Replies to post #176793 on Biotech Values

[DewDiligence]

…there was talk earlier of GILD selling Sovaldi in Egypt for $900 per treatment, which begs the question of whether they can even do so, given that Solvaldi undoubtedly has not been trialed for HCV Genotype 4, which is prevalent in the Middle East.

Sovaldi has been tested in—and is approved for—genotype-4 patients; in the FDA label, the indicated usage for GT4 is 12 weeks of treatment with Sovaldi + PegIFN/ribavirin (just as for GT1): http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204671s000lbl.pdf .